Evaluate the Safety and Clinical Activity of HH2853 — StellaPhase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(25 sites)
United States
Mayo Clinic, Phoenix, Arizona Mayo Clinic, Jacksonville, Florida Mayo Clinic, Rochester, Minnesota NEXT Oncology, San Antonio, Texas China
The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui Beijing Cancer Hospital, Beijing, Beijing Municipality Beijing Cancer Hospital, Beijing, Beijing Municipality Beijing Jishuitan Hospital, Beijing, Beijing Municipality Sun Yat-Sen University Cancer Hospital, Guangzhou, Guangdong Affiliated Tumor Hospital of Guangxi Medical University, Nanning, Guangxi Henan Cancer Hospital, Zhengzhou, Henan Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei Hunan Cancer Hospital, Changsha, Hunan Affiliated Drum Tower Hospital, Medical School of Nanjing University, Nanjing, Jiangsu Liaoning Cancer Hospital&Institute, Shenyang, Liaoning Shengjing Hospital Of China Medical University, Shenyang, Liaoning Linyi Tumor Hospital, Linyi, Shandong
Shanghai Sixth People's Hospital, Shanghai, Shanghai Municipality Zhongshan Hospital Fudan University, Shanghai, Shanghai Municipality Shanxi Cancer Hospital, Taiyuan, Shanxi West China Hospital of Sichuan University, Chengdu, Sichuan Tianjin Cancer Hospital, Tianjin, Tianjin Municipality Zhejiang Cancer Hospital, Hangzhou, Zhejiang Beijing Cancer Hospital, Beijing Sun Yat-Sen University Cancer Hospital, Guangzhou